

- H. Rocha-Ledo. "Microcapsules of alginate/chitosan containing magnetic nanoparticles for controlled release of insulin". *Colloids and Surfaces B: Biointerfaces*, vol. 81, pp. 206-211, 2010.
- [0230] 23. S. Hu, C. Tsai, C. Liao, D. Liu, S. Chen. "Controlled Rupture of Magnetic Polyelectrolyte Micro-capsules for Drug Delivery". *Langmuir*, vol. 24, pp. 1181-11818, 2008.
- [0231] 24. B. Koppolu, M. Rahimi, S. Nattama, A. Wadajkar, K. T. Nguyen. "Development of multiple-layer polymeric particles for targeted and controlled drug delivery". *Nanomedicine*, vol. 6, pp. 355-361, 2010.
- [0232] 25. K. Katagiri, Y. Imai, K. Koumoto. "Variable on-demand release function of magnetoresponsive hybrid capsules". *Journal of Colloid and Interface Science*, vol. 361, pp. 109-114, 2011.
- [0233] 26. A. Bernkop-Schnürch, S. Dünnhaupt. "Chitosan-based drug delivery systems". *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 81, pp. 463-469, 2012.
- [0234] 27. T. Jiang, R. James, S. G. Kumbar. C. T. Laurencin, *Natural and Synthetic Biomedical Polymers*, ch. 5, Elsevier, 2014, 2014.
- [0235] 28. Y. Luo, Q. Wang. "Recent developments of chitosan-based polyelectrolyte complexes with natural polysaccharides for drug delivery". *International Journal of Biological Macromolecules*, vol. 64, pp. 353-367, 2014.
- [0236] 29. M. P. Patel, R. R. Patel, J. K. Patel. "Chitosan Mediated Targeted Drug Delivery System: A Review". *Journal of Pharmaceutical Sciences*, vol. 13, pp. 536-557, 2010.
- [0237] 30. R. M. Patil, P. B. Shete, N. D. Thorat, S. V. Otari, K. C. Barick, A. Prasad, R. S. Ningthoujam, B. M. Tiwale, S. H. Pawar. "Superparamagnetic iron oxide/chitosan core/shells for hyperthermia application: Improved colloidal stability and biocompatibility". *Journal of Magnetism and Magnetic Materials*, vol. 355, pp. 22-30, 2014.
- [0238] 31. D. Zhao, X. Wang, X. Zeng, Q. Xia, J. Tang. "Preparation and inductive heating property of Fe₃O₄-chitosan composite nanoparticles in an AC magnetic field for localized hyperthermia". *Journal of Alloys and Compounds*, vol. 477, pp. 739-743, 2009.
- [0239] 32. H. O. Park, K. Im, S. Lee, D. Kim, D. Lee, Y. Lee, K. Kim, K. Kim. "Preparation and characterization of magnetic chitosan particles for hyperthermia application". *Journal of Magnetism and Magnetic Materials*, vol. 293, pp. 328-333, 2005.
- [0240] 33. C. Sanjai, S. Kothan, P. Gonil, S. Saesoo, W. Sajomsang. "Chitosan-triphosphate nanoparticles for encapsulation of super-paramagnetic iron oxide as an MRI contrast agent". *Carbohydrate Polymers*, vol. 104, pp. 231-237, 2014.
- [0241] 34. Z. Tsai, J. Wang, H. Kuo, C. Shen, J. Wang, T. Yen. "In situ preparation of high relaxivity iron oxide nanoparticles by coating with chitosan: A potential MRI contrast agent useful for cell tracking". *Journal of Magnetism and Magnetic Materials*, vol. 322, pp. 208-213, 2010.
- [0242] 35. Y. Huang, B. Cao, X. Yang, Q. Zhang, X. Han, Z. Guo. "Gd complexes of diethylenetriaminepentaacetic acid conjugates of low-molecular-weight chitosan oligo-saccharide as a new liver-specific MRI contrast agent". *Magnetic Resonance Imaging*, vol. 31, pp. 604-609, 2013.
- [0243] 36. T. Ahmad, H Bae, Y. Iqbal, I. Rhee, S. Hong, Y. Chang, J. Lee, D. Sohn. "Chitosan-coated nickel-ferrite nanoparticles as contrast agents in magnetic resonance imaging". *Journal of Magnetism and Magnetic Materials*, vol. 381, pp. 151-157, 2015.
- [0244] 37. M. Schafer, T. R. Schneider, G. M. Scheldrick. (December, 1996). Crystal structure of vancomycin. *Structure*, 4(12), pp. 1509-1515.
- [0245] 38. M. E. Roy, M. P. Peppers, L. A. Whiteside, R. M. LaZear. (March, 2014). Vancomycin concentration in synovial fluid: direct infection into the knee vs intravenous infusion. *The Journal of Arthroplasty*, 29(3), pp. 564-568.
- [0246] 39. V. P. Mantripragada, A. C. Jayasuriya. (October, 2016). Effect of dual delivery of antibiotics (vancomycin and cefazolin) and BMP-7 from chitosan microparticles on *Staphylococcus epidermidis* and pre-osteoblasts in vitro. *Materials Science and Engineering C*, 67, pp. 409-417.
- [0247] 40. T. Cerchiara et al. (June, 2016). Microparticles based on chitosan/carboxymethylcellulose polyelectrolyte complexes for colon delivery of vancomycin. *Carbohydrate polymers*, 143, pp. 124-130.
- [0248] 41. Z. Yang, J. Liu, J. Gao, S. Chen, G. Huang. (November, 2015). Chitosan coated vancomycin hydrochloride liposomes: characterizations and evaluation. *International Journal of Pharmaceutics*, 495, pp. 508-515.
- [0249] 42. Y. S. Kang, S. Risbud, J. F. Rabolt, P. Stroeve. (1996). Synthesis and Characterization of Nanometer-Size Fe₃O₄ and γ-Fe₂O₃. *Chem. Mater.* 8, pp. 2209-2211.
- [0250] 43. H. Li, L. Qin, Y. Feng, L. Hu, C. Zhou. (January, 2015). Preparation and characterization of highly water-soluble magnetic Fe₃O₄ nanoparticles via surface double-layered self-assembly method of sodium alpha-olefin sulfonate. *Journal of Magnetism and Magnetic Materials*, 384(15), pp. 213-218.
- [0251] 44. H. Lv, R. Jiang, Y. Li, X. Zhang, J. Wang. (March, 2015). Microemulsion-mediated hydrothermal growth of pagoda-like Fe₃O₄ microstructures and their application in a lithium-air battery. *Ceramics International*, 41(7), pp. 8843-8848.
- [0252] 45. S. Kang, S. Risbud, J. F. Rabolt, P. Stroeve. (1996). Synthesis and Characterization of Nanometer-Size Fe₃O₄ and γ-Fe₂O₃. *Chem. Mater.* 8, pp. 2209-2211
- What is claimed is:
1. A microbead comprising cross-linked chitosan, a magnetic nanoparticle, and an agent.
 2. The microbead of claim 1, wherein the chitosan is cross-linked to a polymer.
 3. The microbead of claim 3, wherein the polymer is polyethylene dimethacrylate (PEGDMA).
 4. The microbead of claim 1, wherein the microbead comprises an effective amount of an agent selected from the group consisting of a polypeptide, polynucleotide or small compound.
 5. The microbead of claim 1, wherein the agent is an analgesic, angiogenic agent, antimicrobial, antibody, anti-fungal, anti-inflammatory, anti-thrombotic, chemotherapeutic, growth factor, hormone, or steroid agent.
 6. The microbead of claim 1, wherein the effective amount of the agent is sufficient to reduce the survival or proliferation of a fungal or bacterial cell.